Single-Port Robotic Arm a Gamechanger for Throat Cancer Patients

Author: Lissete Hilton Source: www.physician-news.umiamihealth.org The da Vinci Single-Port robot is an example of how seemingly small advances in technology can drastically change cancer patients’ lives. Sylvester Comprehensive Cancer Center, part of UHealth – the University of Miami Health System, is among the only South Florida health systems to offer the da Vinci Single-Port robot, which surgeons at the cancer center use to remove tumors in the throat. "Being on the cutting edge of robotic surgical advancements that can be applied across multiple specialties allows us to provide the best possible outcomes to our patients," said Dipen J. Parekh, M.D., founding director and chair of the Desai Sethi Urology Institute and director of robotic surgery. Among the patients who benefit most from the new technology are those with squamous cell carcinomas of the tonsil and base of tongue caused by past infection with the human papilloma virus (HPV), according to Donald T. Weed, M.D., co-leader of the Head and Neck Site Disease Group at Sylvester and vice chair for academic affairs in the Department of Otolaryngology at the University of Miami Miller School of Medicine. “Those are the most common throat cancers that we see in non-smokers,” Dr. Weed said. Benefits of the Single-Arm Robot The single-port robot is a gamechanger compared to previous robotic technology because it provides better access through the narrow opening of the throat, said Francisco J. Civantos, M.D., the Virginia M. Horner Endowed Chair in Head and Neck Oncology Research. The older and more widely [...]

2022-06-02T07:32:29-07:00June, 2022|Oral Cancer News|

Leaders in Dentistry: Dr. Ezra Cohen

Source: Dr. Bicuspid By: Donna Domino, Features Editor Date: July 17, 2013 May 21, 2013 — DrBicuspid.com is pleased to present the next installment of Leaders in Dentistry, a series of interviews with researchers, practitioners, and opinion leaders who are influencing the practice of dentistry. We spoke with Ezra Cohen, MD, an associate professor of medicine and the co-director of the head and neck cancer program at the University of Chicago, and the associate director for education at the university’s Comprehensive Cancer Center. Dr. Cohen specializes in head and neck, thyroid, and salivary gland cancers, and is an expert in novel cancer therapies who has conducted extensive research in molecularly targeted agents in the treatment of these cancers. His research interests include discovering how cancers become resistant to existing treatments and overcoming these mechanisms and ways to combine radiotherapy with novel agents. Here Dr. Cohen discusses trends in the incidence, detection, and treatment of oral and head and neck cancers. DrBicuspid.com: What’s the significance of your recent finding that there may be five distinct subgroups of the human papillomavirus (HPV)? Dr. Cohen: The purpose of the research was trying to define molecular subgroups of head and neck cancer (HNC) to inform therapy and outcomes a lot more than we do now as defined by stage and anatomic site. We were taking advantage of a cohort of patients that we treated in a similar fashion at the University of Chicago with a chemotherapy regimen that we commonly use here. The patients [...]

2013-07-19T07:48:02-07:00July, 2013|Oral Cancer News|
Go to Top